UA80117C2 - Фармацевтична композиція, яка містить інгібітор pde4 або pde3/4 та антагоніст гістамінового рецептора - Google Patents

Фармацевтична композиція, яка містить інгібітор pde4 або pde3/4 та антагоніст гістамінового рецептора Download PDF

Info

Publication number: UA80117C2
Authority: UA; Ukraine
Prior art keywords: tetrahydro; imnn; phthalazin; inn; vac
Prior art date: 2002-03-06

Application number

UA20041008055A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Rolph Boime

Daniela Bundschuh

Christian Weimar

Stefan-Lutz Wollin

Original Assignee

Алтана Фарма Аг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-06

Filing date

2003-02-25

Publication date

2007-08-27

2003-02-25 Application filed by Алтана Фарма Аг filed Critical Алтана Фарма Аг

2007-08-27 Publication of UA80117C2 publication Critical patent/UA80117C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 24
239000003112 inhibitor Substances 0.000 title abstract description 30
229940122236 Histamine receptor antagonist Drugs 0.000 title abstract description 10
101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 title abstract 2
239000000739 antihistaminic agent Substances 0.000 title description 6
101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
238000011282 treatment Methods 0.000 claims abstract description 13
208000023504 respiratory system disease Diseases 0.000 claims abstract description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 117
239000013543 active substance Substances 0.000 claims description 89
239000002253 acid Substances 0.000 claims description 75
239000003814 drug Substances 0.000 claims description 32
229940079593 drug Drugs 0.000 claims description 31
150000003839 salts Chemical class 0.000 claims description 30
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 28
229960001803 cetirizine Drugs 0.000 claims description 28
-1 3-cyclopropylmethoxy-4-difluoromethoxy-M-(3,5-dichloropyrid-4-yl)benzamide Chemical compound 0.000 claims description 26
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 24
229960002586 roflumilast Drugs 0.000 claims description 22
239000012453 solvate Substances 0.000 claims description 21
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 19
239000000825 pharmaceutical preparation Substances 0.000 claims description 16
239000004480 active ingredient Substances 0.000 claims description 15
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 14
229940127557 pharmaceutical product Drugs 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 14
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
208000006673 asthma Diseases 0.000 claims description 8
238000002560 therapeutic procedure Methods 0.000 claims description 7
YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 claims description 6
206010006451 bronchitis Diseases 0.000 claims description 6
206010052613 Allergic bronchitis Diseases 0.000 claims description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
201000009961 allergic asthma Diseases 0.000 claims description 2
230000000172 allergic effect Effects 0.000 claims description 2
208000010668 atopic eczema Diseases 0.000 claims description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
206010039083 rhinitis Diseases 0.000 claims description 2
230000001932 seasonal effect Effects 0.000 claims description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 104
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 52
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 39
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 38
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 34
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 33
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 28
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 26
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 24
KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 24
229960003088 loratadine Drugs 0.000 description 23
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 22
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 22
229960001271 desloratadine Drugs 0.000 description 22
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 22
229960000351 terfenadine Drugs 0.000 description 22
229960003592 fexofenadine Drugs 0.000 description 21
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 20
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 20
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 19
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 19
229960004574 azelastine Drugs 0.000 description 18
SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 16
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 16
150000001875 compounds Chemical class 0.000 description 14
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 13
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 13
PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 13
229960000383 azatadine Drugs 0.000 description 13
SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 13
YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 13
229960002071 bepotastine Drugs 0.000 description 13
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 13
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 13
229960003449 epinastine Drugs 0.000 description 13
WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 13
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
229960001158 nortriptyline Drugs 0.000 description 13
ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 12
BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 description 12
UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 12
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 12
229960002881 clemastine Drugs 0.000 description 12
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 12
239000002552 dosage form Substances 0.000 description 12
229950003420 efletirizine Drugs 0.000 description 12
229960001508 levocetirizine Drugs 0.000 description 12
229960001144 mizolastine Drugs 0.000 description 12
229960005328 rupatadine Drugs 0.000 description 12
WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 description 12
ZCGOMHNNNFPNMX-YHYDXASRSA-N Levocabastinum Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)C2CCC(CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-YHYDXASRSA-N 0.000 description 11
PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 11
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 11
229960001971 ebastine Drugs 0.000 description 11
MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 11
229960000325 emedastine Drugs 0.000 description 11
229960003223 tripelennamine Drugs 0.000 description 11
239000005711 Benzoic acid Substances 0.000 description 10
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
229960003792 acrivastine Drugs 0.000 description 10
235000010233 benzoic acid Nutrition 0.000 description 10
229940098779 methanesulfonic acid Drugs 0.000 description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 9
KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 9
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 9
SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 9
229960001882 dexchlorpheniramine Drugs 0.000 description 9
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 8
229950001653 cilomilast Drugs 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
MIXLZCYFMQNQDD-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-N'-hydroxy-1,3-thiazole-2-carboximidamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CSC(C(N)=NO)=N1 MIXLZCYFMQNQDD-UHFFFAOYSA-N 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
VBSPHZOBAOWFCL-UHFFFAOYSA-N setastine Chemical compound C=1C=CC=CC=1C(C=1C=CC(Cl)=CC=1)(C)OCCN1CCCCCC1 VBSPHZOBAOWFCL-UHFFFAOYSA-N 0.000 description 7
229950003911 setastine Drugs 0.000 description 7
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 6
LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 6
102000000543 Histamine Receptors Human genes 0.000 description 6
108010002059 Histamine Receptors Proteins 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 5
241001024304 Mino Species 0.000 description 5
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 5
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 5
230000037396 body weight Effects 0.000 description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
229940044551 receptor antagonist Drugs 0.000 description 4
239000002464 receptor antagonist Substances 0.000 description 4
AKTXOQVMWSFEBQ-LCYFTJDESA-N (5z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(\C=C/2C(N=C(N)S\2)=O)=C1 AKTXOQVMWSFEBQ-LCYFTJDESA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000013566 allergen Substances 0.000 description 3
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229950000393 darbufelone Drugs 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
210000003630 histaminocyte Anatomy 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003380 propellant Substances 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
OGSULPWGXWPZOJ-UHFFFAOYSA-N 2-(1,8-naphthyridin-2-yl)-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(C3=NC4=NC=CC=C4C=C3)=CC=C21 OGSULPWGXWPZOJ-UHFFFAOYSA-N 0.000 description 2
RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 2
YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 2
KKWWESVWJKAKNI-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-1,3-thiazole-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CSC(C(N)=O)=N1 KKWWESVWJKAKNI-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000014181 Bronchial disease Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 1
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
UXBLDQMSOWQULB-UHFFFAOYSA-N 3-amino-2-methyl-6,7,8,9-tetrahydro-5h-cyclohepta[2,3]thieno[2,4-d]pyrimidin-4-one Chemical compound C1CCCCC2=C1SC1=C2C(=O)N(N)C(C)=N1 UXBLDQMSOWQULB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
AIZALTNNDIGFRS-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-2-(1-propan-2-ylpiperidin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(C1CC=CCC1C1=O)=NN1C1CCN(C(C)C)CC1 AIZALTNNDIGFRS-UHFFFAOYSA-N 0.000 description 1
JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000001692 EU approved anti-caking agent Substances 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000018569 Respiratory Tract disease Diseases 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical class [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000011575 calcium Chemical class 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002884 effect on inflammation Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical class NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002050 international nonproprietary name Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000006072 paste Substances 0.000 description 1
IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
SNWQKAWITMVCQW-UHFFFAOYSA-N phthalylsulfacetamide Chemical compound C1=CC(S(=O)(=O)NC(=O)C)=CC=C1NC(=O)C1=CC=CC=C1C(O)=O SNWQKAWITMVCQW-UHFFFAOYSA-N 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000002226 simultaneous effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000010936 titanium Chemical class 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

UA20041008055A 2002-03-06 2003-02-25 Фармацевтична композиція, яка містить інгібітор pde4 або pde3/4 та антагоніст гістамінового рецептора UA80117C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02004987		2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en)	2002-03-06	2003-02-25	Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (1)

Publication Number	Publication Date
UA80117C2 true UA80117C2 (uk)	2007-08-27

Family

ID=27771841

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041008055A UA80117C2 (uk)	2002-03-06	2003-02-25	Фармацевтична композиція, яка містить інгібітор pde4 або pde3/4 та антагоніст гістамінового рецептора

Country Status (31)

Country	Link
US (1)	US20050112069A1 (sr)
EP (2)	EP1849468B1 (sr)
JP (1)	JP5150034B2 (sr)
KR (1)	KR20040095255A (sr)
CN (1)	CN101257904A (sr)
AR (1)	AR038858A1 (sr)
AT (1)	ATE369134T1 (sr)
AU (1)	AU2003212268B2 (sr)
BR (1)	BR0308220A (sr)
CA (1)	CA2478612C (sr)
CO (1)	CO5611148A2 (sr)
CY (2)	CY1106927T1 (sr)
DE (1)	DE60315426T2 (sr)
DK (2)	DK1482938T3 (sr)
EA (2)	EA010886B1 (sr)
ES (2)	ES2400670T3 (sr)
HR (1)	HRP20040909B1 (sr)
IL (1)	IL163336A (sr)
IS (2)	IS2536B (sr)
MX (1)	MXPA04008460A (sr)
NO (1)	NO335254B1 (sr)
NZ (1)	NZ535611A (sr)
PL (1)	PL211574B1 (sr)
PT (2)	PT1482938E (sr)
RS (1)	RS51018B (sr)
SG (1)	SG160197A1 (sr)
SI (2)	SI1849468T1 (sr)
TW (1)	TWI347845B (sr)
UA (1)	UA80117C2 (sr)
WO (1)	WO2003074055A1 (sr)
ZA (1)	ZA200407104B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8067433B2 (en) *	2005-11-09	2011-11-29	Zalicus Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008074803A2 (en) *	2006-12-20	2008-06-26	Glaxo Group Limited	4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
US20090182035A1 (en) *	2007-04-11	2009-07-16	Alcon Research, Ltd.	Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2682730A1 (en) *	2007-04-11	2008-10-23	Alcon Research, Ltd.	Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009067597A1 (en) *	2007-11-21	2009-05-28	Decode Genetics Ehf	4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) *	2007-12-12	2009-06-17	한미약품 주식회사	베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
RS55624B1 (sr)	2011-02-07	2017-06-30	Scipharm Sàrl	Nova kompozicija za lečenje cistične fibroze
KR102226833B1 (ko) *	2013-06-28	2021-03-12	한미약품 주식회사	레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CN106604747A (zh) *	2014-08-26	2017-04-26	基础应用医学研究基金会	用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
NZ731344A (en)	2014-10-09	2018-08-31	Guangdong Raynovent Biotech Co Ltd	Hydroxyl purine compounds and applications thereof
CN109956947A (zh) *	2017-12-25	2019-07-02	江苏恒瑞医药股份有限公司	一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2847693A1 (de) *	1978-11-03	1980-05-22	Hoechst Ag	Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en)	1991-03-21	1994-07-07	Novartis Ag	Inhaler
CZ290266B6 (cs) *	1993-07-02	2002-06-12	Byk Gulden Lomberg Chemische Fabrik Gmbh	Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5900421A (en) *	1997-02-11	1999-05-04	Sepracor Inc.	Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) *	1997-11-07	1999-11-23	Schering Corporation	H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) *	1998-11-10	2000-06-06	Panacea Biotec Ltd	Composição antialérgica e antiinflamatória
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
AU781137B2 (en) *	1999-10-25	2005-05-05	Altana Pharma Ag	Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) *	2001-06-20	2001-08-15	Glaxo Group Ltd	Novel use

2003
- 2003-02-20 TW TW092103525A patent/TWI347845B/zh not_active IP Right Cessation
- 2003-02-25 KR KR10-2004-7013742A patent/KR20040095255A/ko not_active Ceased
- 2003-02-25 DE DE60315426T patent/DE60315426T2/de not_active Expired - Lifetime
- 2003-02-25 RS YUP-780/04A patent/RS51018B/sr unknown
- 2003-02-25 CN CNA038053349A patent/CN101257904A/zh active Pending
- 2003-02-25 MX MXPA04008460A patent/MXPA04008460A/es active IP Right Grant
- 2003-02-25 ES ES07112823T patent/ES2400670T3/es not_active Expired - Lifetime
- 2003-02-25 AT AT03708130T patent/ATE369134T1/de active
- 2003-02-25 HR HR20040909 patent/HRP20040909B1/xx not_active IP Right Cessation
- 2003-02-25 PT PT03708130T patent/PT1482938E/pt unknown
- 2003-02-25 SG SG200606154-3A patent/SG160197A1/en unknown
- 2003-02-25 BR BR0308220-2A patent/BR0308220A/pt not_active Application Discontinuation
- 2003-02-25 ES ES03708130T patent/ES2291618T3/es not_active Expired - Lifetime
- 2003-02-25 NZ NZ535611A patent/NZ535611A/xx not_active IP Right Cessation
- 2003-02-25 SI SI200332245T patent/SI1849468T1/sl unknown
- 2003-02-25 US US10/506,875 patent/US20050112069A1/en not_active Abandoned
- 2003-02-25 PL PL371056A patent/PL211574B1/pl unknown
- 2003-02-25 DK DK03708130T patent/DK1482938T3/da active
- 2003-02-25 CA CA2478612A patent/CA2478612C/en not_active Expired - Fee Related
- 2003-02-25 WO PCT/EP2003/001876 patent/WO2003074055A1/en not_active Ceased
- 2003-02-25 EA EA200601592A patent/EA010886B1/ru not_active IP Right Cessation
- 2003-02-25 JP JP2003572572A patent/JP5150034B2/ja not_active Expired - Fee Related
- 2003-02-25 SI SI200330970T patent/SI1482938T1/sl unknown
- 2003-02-25 AU AU2003212268A patent/AU2003212268B2/en not_active Ceased
- 2003-02-25 EP EP07112823A patent/EP1849468B1/en not_active Expired - Lifetime
- 2003-02-25 EA EA200401137A patent/EA007903B1/ru not_active IP Right Cessation
- 2003-02-25 UA UA20041008055A patent/UA80117C2/uk unknown
- 2003-02-25 EP EP03708130A patent/EP1482938B1/en not_active Expired - Lifetime
- 2003-02-25 PT PT71128235T patent/PT1849468E/pt unknown
- 2003-02-25 DK DK07112823.5T patent/DK1849468T3/da active
- 2003-02-27 AR ARP030100646A patent/AR038858A1/es unknown
2004
- 2004-08-03 IL IL163336A patent/IL163336A/en not_active IP Right Cessation
- 2004-09-03 CO CO04086713A patent/CO5611148A2/es active IP Right Grant
- 2004-09-03 IS IS7438A patent/IS2536B/is unknown
- 2004-09-06 ZA ZA200407104A patent/ZA200407104B/en unknown
- 2004-10-06 NO NO20044230A patent/NO335254B1/no not_active IP Right Cessation
2007
- 2007-10-11 CY CY20071101307T patent/CY1106927T1/el unknown
2008
- 2008-09-04 IS IS8760A patent/IS8760A/is unknown
2013
- 2013-02-21 CY CY20131100163T patent/CY1113894T1/el unknown

Also Published As

Publication number	Publication date
SI1482938T1 (sl)	2007-12-31
RS78004A (sr)	2006-12-15
DK1482938T3 (da)	2007-12-03
AU2003212268A1 (en)	2003-09-16
EP1482938B1 (en)	2007-08-08
EA200401137A1 (ru)	2005-04-28
ATE369134T1 (de)	2007-08-15
EP1849468B1 (en)	2012-12-05
PT1849468E (pt)	2013-02-27
EA007903B1 (ru)	2007-02-27
HK1071308A1 (en)	2005-07-15
EP1482938A1 (en)	2004-12-08
CA2478612A1 (en)	2003-09-12
IS2536B (is)	2009-08-15
WO2003074055A1 (en)	2003-09-12
SI1849468T1 (sl)	2013-03-29
ES2400670T3 (es)	2013-04-11
DE60315426T2 (de)	2008-07-03
JP5150034B2 (ja)	2013-02-20
AU2003212268B2 (en)	2008-09-11
CO5611148A2 (es)	2006-02-28
ES2291618T3 (es)	2008-03-01
AR038858A1 (es)	2005-01-26
PT1482938E (pt)	2007-11-15
CY1113894T1 (el)	2016-07-27
CN101257904A (zh)	2008-09-03
EA200601592A1 (ru)	2006-12-29
EP1849468A2 (en)	2007-10-31
JP2005524666A (ja)	2005-08-18
IS8760A (is)	2008-09-04
HRP20040909A2 (en)	2005-08-31
US20050112069A1 (en)	2005-05-26
SG160197A1 (en)	2010-04-29
HRP20040909B1 (en)	2012-11-30
NZ535611A (en)	2006-03-31
NO335254B1 (no)	2014-10-27
DE60315426D1 (de)	2007-09-20
EA010886B1 (ru)	2008-12-30
DK1849468T3 (da)	2013-02-04
CA2478612C (en)	2013-12-10
PL371056A1 (en)	2005-06-13
KR20040095255A (ko)	2004-11-12
BR0308220A (pt)	2005-01-04
MXPA04008460A (es)	2004-12-06
RS51018B (sr)	2010-10-31
IS7438A (is)	2004-09-03
CY1106927T1 (el)	2012-09-26
IL163336A (en)	2009-02-11
NO20044230L (no)	2004-12-06
TW200306855A (en)	2003-12-01
TWI347845B (en)	2011-09-01
EP1849468A3 (en)	2007-11-07
PL211574B1 (pl)	2012-05-31
ZA200407104B (en)	2006-12-27

Publication	Publication Date	Title
JP6924267B2 (ja)	2021-08-25	ピロロ［１，２−ｂ］ピリダジン誘導体
US12060366B2 (en)	2024-08-13	Bispecific degraders
US20100130537A1 (en)	2010-05-27	Cinnamide compounds for dementia
TW200902015A (en)	2009-01-16	Amino-heterocyclic compounds
AU2007276804A1 (en)	2008-01-31	Inhibitors of undecaprenyl pyrophosphate synthase
CA2802588A1 (en)	2011-12-22	Heteroaryl imidazolone derivatives as jak inhibitors
RU2006136879A (ru)	2008-04-27	Бензодиазипины для лечения или профилактики инфекции rsv
JP2818299B2 (ja)	1998-10-30	ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
WO2016088813A1 (ja)	2016-06-09	新規ジアザビシクロ［２．２．２］オクタン誘導体
JP5150034B2 (ja)	2013-02-20	Ｐｄｅ４またはｐｄｅ３／４インヒビターとヒスタミンレセプターアンタゴニストとの医薬組成物
KR20170141774A (ko)	2017-12-26	항바이러스 및 항염증 치료제의 치료 조합물
US11091485B2 (en)	2021-08-17	Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
CA2624497C (en)	2014-11-18	Antituberculosis drug combination comprising oxazole compounds
US12071431B2 (en)	2024-08-27	Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta
CN114057754A (zh)	2022-02-18	含氮桥环类衍生物、其制备方法及其在医药上的应用
TW200815440A (en)	2008-04-01	Modulators of muscarinic receptors
CN114621230B (zh)	2023-06-16	含氮杂环化合物、其制备方法及其在医药上的应用
EP2999469A1 (de)	2016-03-30	Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen ( on-demand") kontrazeption
US20230365531A1 (en)	2023-11-16	Inhibitors of human respiratory syncytial virus and metapneumo virus
CN114539142A (zh)	2022-05-27	吡啶酮类化合物，其药物组合物、制备方法和应用
CN114276351A (zh)	2022-04-05	含氮杂环类衍生物、其制备方法及其在医药上的应用
JPH02501574A (ja)	1990-05-31	増殖過剰性皮膚疾患処置用組成物
TW201014853A (en)	2010-04-16	Heterocyclic phosphodiesterase inhibitors